Clinical trial HATCY study
A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Kiadis Pharma |
| EudraCT Identifier | 2016-004672-21 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02999854 |
| Inclusion criteria | no suitable HLA-matched sibling or unrelated donor / no prior allogeneic stem cell transplantation/ AML, ALL or MDS |
| Last update |